CT-based assessment of skeletal deterioration after high-dose denosumab discontinuation in metastatic breast cancer.
Authors
Affiliations (4)
Affiliations (4)
- Department of Orthopaedic Surgery, Fukuyama City Hospital, 5-23-1, Zaocho, Fukuyama, Hiroshima, Japan.
- Department of Orthopaedic Medical Engineering, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, Japan. [email protected].
- Department of Breast and Thyroid Surgery, Fukuyama City Hospital, 5-23-1, Zaocho, Fukuyama, Hiroshima, Japan.
- Division of Information Science, Graduate School of Science and Technology, Nara Institute of Science and Technology, 8916-5, Takayamacho Ikoma, Nara, Japan.
Abstract
The effects of discontinuing oncology-dose denosumab on bone mineral density (BMD) remain unclear. We investigated longitudinal BMD changes after discontinuation in patients with metastatic breast cancer. We conducted a single-center retrospective longitudinal cohort study of 72 women with breast cancer and bone metastases who discontinued treatment with denosumab 120 mg. An exploratory breast cancer control cohort without bone metastases or prior denosumab exposure, frequency-matched by age at the group level (n = 32), was also evaluated. BMD at the lumbar spine and proximal femur was quantified from routine non-contrast computed tomography (CT) using an artificial intelligence-driven pipeline, and changes from baseline were assessed at prespecified intervals of 3, 6, 9, 12, 18, and 24 months. Skeletal-related events (SREs) before and after discontinuation were also evaluated. Changes were analyzed using linear mixed-effects models with categorical follow-up time and random intercepts. Medication-related osteonecrosis of the jaw was the most common reason for denosumab discontinuation (75.0%). BMD declined over time at both sites, with significant reductions at 12, 18, and 24 months of 7.0%, 10.2%, and 11.3% at the lumbar spine and 3.8%, 10.0%, and 10.7% at the proximal femur, respectively. In the exploratory control cohort, median 24-month BMD changes were - 1.6% (proximal femur) and - 3.2% (lumbar spine). Post-discontinuation SREs occurred in 12 patients (16.7%), seven of whom had no prior SRE. Discontinuation of oncology-dose denosumab was followed by time-dependent CT-derived BMD loss at both sites, with significant reductions from 12 months onward. Prospective studies are needed to clarify the clinical implications and optimal post-discontinuation management.